PT Millennium Pharmacon International Tbk
IIDX:SDPC204.00
IDR
+4.00
(+2.00%)
ISIN
ID1000072804
Return %
Stock
S&P 500
1Y
47.83
14.20
3Y
30.77
81.12
5Y
51.11
68.34
Capital Structure
IDR
•
in mil. unless spec.Working Capital
IDR
•
in mil. unless spec.Growth Rates
IDR
•
in mil. unless spec.Quarterly Revenue
IDR
•
in mil. unless spec.Quarterly Earnings Per Share
IDR
•
in mil. unless spec.Quarterly Dividends Per Share
IDR
•
in mil. unless spec.Company Description
- CEO
- Ahmad bin Abu Bakar
- Full Time Employees
- 1,197
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Crown Bungur Arteri Jakarta JK Indonesia 12220
- IPO Date
- May 7, 1990
- Website
- mpi-indonesia.co.id
- Similar Companies
- Business
- PT Millennium Pharmacon International Tbk is an Indonesia-based pharmaceutical distribution company engaged primarily in the trading and distribution of prescription medicines, non-prescription medicines, medical devices, food supplements, and diagnostics across Indonesia. Founded in 1952 and headquartered in South Jakarta, the company operates a comprehensive logistics and distribution network with approximately 36 branch offices and a central warehouse. Its core product portfolio includes branded pharmaceuticals, generic drugs, over-the-counter (OTC) products, diagnostic supplies, and medical devices, catering to hospitals, clinics, pharmacies, and other healthcare providers throughout Indonesia. PT Millennium Pharmacon International Tbk is a subsidiary of Pharmaniaga International Corporation Sdn. Bhd., holding a controlling stake, which strategically integrates the company into a broader Southeast Asian pharmaceutical ecosystem. The company has been actively pursuing inorganic growth strategies to enhance its market position and reduce dependence on third-party products. This includes recent capital injections into subsidiaries such as PT Digital Pharma Andalan and plans for acquisitions focused on expanding its OTC product offerings and medical device segments. Additionally, the company has expanded its distribution footprint by opening new branch offices in various regions, notably establishing its 36th branch to widen market reach. Key operational updates include ongoing efforts to boost manufacturing capabilities and product development through its parent company Pharmaniaga, which supports MPI with access to generic drug manufacturing and new product pipelines such as vaccines and insulin. These expansions align with MPI’s goal to position itself for significant growth by broadening its distribution scope and product base while leveraging Pharmaniaga's expertise and resources. The company's presence addresses both prescription and non-prescription segments and a growing portfolio of medical devices, making it a major pharmaceutical logistics and distribution player in Indonesia's healthcare sector. Overall, PT Millennium Pharmacon International Tbk stands as a leading pharmaceutical distributor with a diversified product offering, a growing strategic footprint in Indonesia, and a parent-company-backed expansion strategy targeting enhanced product manufacturing and broader regional market penetration. This description incorporates the company's main products, detailed services, recent structural and strategic developments, operational scale, and its industry positioning within Indonesia and the broader pharmaceutical distribution landscape.